var data={"title":"Tipranavir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tipranavir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/43924?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tipranavir-drug-information\" class=\"drug drug_general\">see &quot;Tipranavir: Drug information&quot;</a> and <a href=\"topic.htm?path=tipranavir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tipranavir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708929\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Clinical hepatitis and hepatic decompensation, including some fatalities, have been reported. Extra vigilance is warranted in patients with chronic hepatitis B or hepatitis C coinfection, as these patients have an increased risk of hepatotoxicity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Intracranial hemorrhage:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Both fatal and nonfatal intracranial hemorrhage have been reported.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786677\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aptivus</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2935530\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aptivus</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1039236\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">HIV Agents (Anti-HIV Agents)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Protease Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1039267\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tipranavir-drug-information\" class=\"drug drug_general\">see &quot;Tipranavir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>HIV-1 infection, treatment:</b> <b>Note:</b> Use in combination with other antiretroviral agents. Not recommended for treatment-na&iuml;ve patients. Coadministration with ritonavir is required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;2 years: Not recommended for use</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Oral: Tipranavir 14 mg/kg (maximum: 500 mg) <b>plus</b> ritonavir 6 mg/kg (maximum: 200 mg) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If intolerance or toxicity develops and virus is not resistant to multiple protease inhibitors: May decrease dose to: Tipranavir 12 mg/kg <b>plus</b> ritonavir 5 mg/kg twice daily; do not exceed adult doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA-directed dosing: Oral: Tipranavir 375 mg/m<sup>2</sup> (maximum: 500 mg) <b>plus</b> ritonavir 150 mg/m<sup>2</sup> (maximum: 200 mg) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If intolerance or toxicity develops and virus is not resistant to multiple protease inhibitors: May decrease dose to: Tipranavir 290 mg/m<sup>2</sup> <b>plus</b> ritonavir 115 mg/m<sup>2</sup> twice daily; do not exceed adult doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>HIV-1 infection, treatment:</b> Oral: Use in combination with other antiretroviral agents. Not recommended for treatment na&iuml;ve patients. <b>Note:</b> Coadministration with ritonavir is required. Tipranavir 500 mg <b>plus</b> ritonavir 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Guidelines state that dosage adjustment is not required (HHS [adult] 2015; HHS [pediatric] 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment (Child-Pugh class B or C): Use is contraindicated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786742\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptivus: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptivus: 100 mg/mL (95 mL) [contains polyethylene glycol, propylene glycol, tocophersolan; buttermint-butter toffee flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786679\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1039272\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Coadministration with ritonavir is required. In pediatric patients, may administer tipranavir <b>plus</b> ritonavir <b>capsules</b> or <b>solution</b> together with food (HHS [pediatric] 2016) and in adults without regard to meals. Administer tipranavir <b>plus</b> ritonavir <b>tablets</b> at the same time with food. Swallow capsules whole; do not chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786723\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule: Prior to opening bottle, store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). After bottle is opened, may be stored at 25&deg;C (77&deg;F) for up to 60 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral solution: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). After bottle is open, use within 60 days.  Do not refrigerate or freeze oral solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1039237\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Treatment of HIV-1 infections in combination with ritonavir and other antiretroviral agents in patients who are highly treatment-experienced and multiprotease inhibitor-resistant (FDA approved in ages &ge;2 years and adults). <b>Note:</b> HIV regimens consisting of <b>three</b> antiretroviral agents are strongly recommended. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708074\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786714\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, drowsiness, fatigue, headache, insomnia, intracranial hemorrhage, malaise, peripheral neuropathy, sleep disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash (more common children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration, diabetes mellitus, hypercholesterolemia (&gt;300 mg/dL), hyperglycemia, hypertriglyceridemia (&gt;400 mg/dL), increased amylase, increased gamma-glutamyl transferase, lipodystrophy (acquired), lipohypertrophy, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distension, abdominal pain, anorexia, decreased appetite, diarrhea (less common in children), dyspepsia, flatulence, gastroesophageal reflux disease, increased serum lipase, nausea, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, decreased white blood cell count, hemorrhage (children), neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic failure, hepatitis, hyperbilirubinemia, increased serum ALT, increased serum AST, increased serum transaminases, liver steatosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Immune reconstitution syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Amyotrophy (facial), increased creatine phosphokinase (children), lipoatrophy, muscle cramps, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (children), dyspnea, epistaxis (children), flu-like symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Drug toxicity (mitochondrial damage), fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786708\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coadministration of tipranavir/ritonavir with drugs highly dependent upon CYP3A for clearance or potent CYP3A inducers, including alfuzosin, amiodarone, bepridil, cisapride, ergot derivatives (eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine), flecainide, lovastatin, lurasidone, midazolam (oral), pimozide, propafenone, quinidine, rifampin, sildenafil (for pulmonary arterial hypertension [eg, Revatio]), simvastatin, St John&rsquo;s wort, and triazolam; moderate-to-severe hepatic impairment (Child-Pugh class B or C)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to tipranavir or any component of the product, concurrent therapy with colchicine, astemizole (not available in Canada), terfenadine (not available in Canada), or quetiapine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786709\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: In combination with ritonavir, clinical hepatitis and hepatic decompensation, including some fatalities, have been reported.  May  exacerbate pre-existing hepatic dysfunction (causal relationship not established); patients with chronic hepatitis B or C coinfection have an increased risk.</b> Assess liver function tests at baseline and frequently throughout treatment. Monitor patients closely, especially those with chronic hepatitis B or C coinfection; discontinue use if signs or symptoms of toxicity occur (eg, fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, acholic stools, liver tenderness or hepatomegaly) or if asymptomatic AST/ALT elevations &gt;10 times ULN or AST/ALT elevations &gt;5 to 10 times ULN concurrently with total bilirubin &gt;2.5 times ULN occur. Treatment experienced patients with chronic hepatitis B or C coinfection or elevated transaminases are at ~2-fold risk for developing Grade 3 or 4 transaminase elevations or hepatic decompensation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Increased cholesterol: With coadministered ritonavir, increases in total cholesterol and triglycerides have been reported; screening should be done prior to therapy and periodically throughout treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intracranial hemorrhage: <b>[US Boxed Warning]: Use in combination with ritonavir has been associated with rare reports of fatal and nonfatal intracranial hemorrhage; causal relationship not established.</b> Events often occurred in patients with medical conditions (eg, CNS lesions, head trauma, recent neurosurgery, coagulopathy, alcohol abuse) or concurrent medications which may have influenced these events. No abnormal pattern of coagulation parameters has been observed in patients in general, or preceding intracranial hemorrhage development.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin reactions: Has been associated with a variety of skin reactions including rash (urticarial or maculopapular) and possible photosensitivity. In some cases rash was accompanied by joint pain or stiffness, throat tightness or generalized pruritus. Risk of rash increases in patients with lower CD4 counts. Discontinue treatment if severe skin rash develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfonamide allergy: Use with caution in patients with sulfonamide allergy; contains a sulfonamide moiety. The potential for cross-sensitivity between drugs in the sulfonamide class and tipranavir is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in HIV-1 infected  patients receiving protease inhibitors. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemophilia A or B: Use with caution in patients with hemophilia A or B; increased bleeding (including spontaneous skin hematomas and hemarthrosis) during protease inhibitor therapy has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with Child-Pugh class A (mild) hepatic impairment; contraindicated in Child-Pugh class B or C (moderate-to-severe) impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> &bull; Platelet aggregation: May impair platelet aggregation, resulting in bleeding; use with caution in patients who may be at risk for increased bleeding (trauma, surgery, other medical conditions, or taking antiplatelet agents, anticoagulants, or supplemental high doses of vitamin E). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage forms specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ethanol: Capsules contain dehydrated alcohol 7% w/w (0.1 g per capsule).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25955859\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Skin rash may occur with tipranavir plus ritonavir use, including urticarial rash, maculopapular rash, or photosensitivity; may be accompanied by joint pain or stiffness, throat tightness, or generalized pruritus; reported incidence (all grades): Pediatric patients: 21%, adults: 8% to 10%; median onset: 53 days; treatment may be continued if rash is mild to moderate (rash may resolve; median duration: 22 days); discontinue therapy in cases of severe rash. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Tipranavir oral solution contains vitamin E (116 units/mL), which is significantly higher than the RDA; avoid taking additional vitamin E (other than a daily multivitamin). The recommended pediatric dose of tipranavir (14 mg/kg body weight) results in a vitamin E dose of 16 units/kg body weight per day, significantly higher than the reference daily intake for vitamin E (10 units) and close to the upper limit of tolerability for children. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786718\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BSEP/ABCB11, CYP2D6 (strong)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786717\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=89428&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Tipranavir may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: Tipranavir may increase the serum concentration of Amiodarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Tipranavir may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Please refer to the full interaction monograph for details concerning the recommended dose adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Tipranavir may increase the serum concentration of AtorvaSTATin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Benzhydrocodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bepridil: Tipranavir may increase the serum concentration of Bepridil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: Tipranavir may decrease the serum concentration of Boceprevir. Boceprevir may decrease the serum concentration of Tipranavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of Tipranavir. Tipranavir may increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg/day or every other day in adult patients taking tipranavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting tipranavir/ritonavir; wait at least 10 days before restarting bosentan.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose to 50% of usual with a strong CYP2D6 inhibitor; this recommendation does not apply if treating major depressive disorder.  Reduce to 25% of usual if used with both a strong CYP2D6 inhibitor and a CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If used, monitor for CCB toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir, tipranavir, and darunavir/cobicistat use with bepridil is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholic Acid: BSEP/ABCB11 Inhibitors may decrease the excretion of Cholic Acid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed. Clarithromycin may increase the serum concentration of Protease Inhibitors.  Management: Avoid clarithromycin adult doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Tipranavir. However, the magnitude of this change is unclear, and dosing recommendations for this combination are not available.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: Tipranavir may increase the serum concentration of Colchicine.  Management: Colchicine should not be used with tipranavir in patients with impaired renal or hepatic function.  In those with normal renal and hepatic function, reduced colchicine doses (as directed) are required if used with tipranavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the incidences of neutropenia, infection, and mucositis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Protease Inhibitors. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Ajmaline; Dapoxetine; Indoramin; Tamoxifen; Timolol (Ophthalmic); Tropisetron.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Dapoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Protease Inhibitors may decrease the serum concentration of Delavirdine. Delavirdine may increase the serum concentration of Protease Inhibitors. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deutetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Deutetrabenazine.  Management: The total daily dose of deutetrabenazine should not exceed 36 mg, and the maximum single dose of deutetrabenazine should not exceed 18 mg with concurrent use of a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextromethorphan: Tipranavir may increase the serum concentration of Dextromethorphan.  Management: Consider avoiding dextromethorphan in patients taking tipranavir. If combined, monitor closely for increased dextromethorphan effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Tipranavir may decrease the serum concentration of Didanosine.  Management: It is recommended that didanosine be administered at least 2 hours apart from tipranavir in order to minimize any potential dosage form-related interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May enhance the adverse/toxic effect of Tipranavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Tipranavir may decrease the serum concentration of Dolutegravir. Specifically, Tipranavir/Ritonavir may decrease the serum concentration of Dolutegravir.  The individual contributions of Tipranavir and Ritonavir to this effect are unknown.  Management: Increase dolutegravir dose to 50 mg twice daily in patients receiving tipranavir/ritonavir. Seek alternatives to tipranavir/ritonavir in INSTI experienced patients with suspected INSTI resistance or certain INSTI associated resistance substitutions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to strong CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Eliglustat.  Management: Reduce the eliglustat dose to 84 mg daily. Avoid use of eliglustat in combination with a strong CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Tipranavir may increase the serum concentration of Eluxadoline.  Management: Decrease the eluxadoline dose to 75 mg twice daily if combined with tipranavir and monitor patients for increased eluxadoline effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enfuvirtide: Protease Inhibitors may increase the serum concentration of Enfuvirtide. Enfuvirtide may increase the serum concentration of Protease Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives. <b> Exceptions: </b>Cabergoline; Nicergoline; Pergolide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives. Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Tipranavir may decrease the serum concentration of Etravirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Tipranavir may increase the serum concentration of Flecainide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Tipranavir. Management: Limit fluconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluticasone (Oral Inhalation): Tipranavir may increase the serum concentration of Fluticasone (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Fosphenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: Tipranavir may increase the serum concentration of Grazoprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of HYDROcodone. Specifically, concentrations of hydromorphone may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Tipranavir may increase the serum concentration of Itraconazole.  Management: Limit itraconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Tipranavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit ketoconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Tipranavir may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: Tipranavir may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Tipranavir may decrease the serum concentration of Methadone. More specifically, the combination of Tipranavir and Ritonavir may decrease Methadone serum concentrations. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.  Management: Consider an alternative for one of the interacting drugs in order to avoid metoprolol toxicity. If the combination must be used, monitor response to metoprolol closely. Metoprolol dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Tipranavir. A disulfiram-like reaction may occur due to the alcohol contained in tipranavir capsules.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Tipranavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.  Management: Consider alternatives to, or reduced doses of, nefazodone in patients treated with HIV protease inhibitors.  Monitor patients receiving these combinations closely for toxic effects of nefazodone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MMDL metabolite may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MDL metabolite may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: BSEP/ABCB11 Inhibitors may increase serum concentrations of the active metabolite(s) of Obeticholic Acid.  Management: Avoid concomitant use of obeticholic acid and bile salt efflux pump (BSEP) inhibitors if possible. If concomitant therapy is necessary, monitor patients for elevated liver transaminases and elevated bilirubin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of PHENobarbital.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Protease Inhibitors may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Tipranavir may increase the serum concentration of Progestins (Contraceptive).  Management: Use an alternative or additional method of contraception due to possibly decreased contraceptive effectiveness. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: Tipranavir may increase the serum concentration of Propafenone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: Tipranavir may decrease the serum concentration of Protease Inhibitors. <b> Exceptions: </b>Ritonavir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors (PI).  Darunavir/cobicistat not recommended with PI that require boosting.Other combos may require dose changes.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: Tipranavir may decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Tipranavir may increase the serum concentration of QuiNIDine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Tipranavir may decrease the serum concentration of Raltegravir.  Management: Concurrent use of tipranavir/ritonavir with once-daily raltegravir (Isentress HD) is not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifabutin: Tipranavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Tipranavir may increase the serum concentration of Rifabutin.  Management: Reduce rifabutin doses. Tipranavir US labeling recommends a decrease of at least 75%, to 150 mg every other day or 3 times per week for adults. Clinical guidelines recommend 150 mg daily or 300 mg 3 times per week when used with tipranavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Tipranavir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Protease Inhibitors may increase the serum concentration of Riociguat.  Management: Consider starting with a reduced riociguat dose of 0.5 mg three times a day (for adults).  Patients receiving such a combination should also be monitored extra closely for signs or symptoms of hypotension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start at the lowest rosuvastatin dose and monitor for toxicity. See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salmeterol: Tipranavir may increase the serum concentration of Salmeterol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: Protease Inhibitors may increase the serum concentration of Simeprevir. Simeprevir may increase the serum concentration of Protease Inhibitors. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sofosbuvir: Tipranavir may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Tipranavir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tadalafil: Tipranavir may increase the serum concentration of Tadalafil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Tipranavir may decrease the serum concentration of Telaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Alafenamide: Tipranavir may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Disoproxil Fumarate: May decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: CYP2D6 Inhibitors may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timolol (Ophthalmic): CYP2D6 Inhibitors (Strong) may increase the serum concentration of Timolol (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Strong) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraZODone: Tipranavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with tipranavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tropisetron: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tropisetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Valbenazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Protease Inhibitors may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): Tipranavir may enhance the adverse/toxic effect of Vitamin E (Systemic).  Management: Patients taking tipranavir oral solution are advised to avoid taking additional vitamin E, beyond the amounts contained in a multivitamin product.  This interaction does not apply to tipranavir capsules.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vortioxetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Vortioxetine.  Management: The vortioxetine dose should be reduced by 50% when used together with a strong CYP2D6 inhibitor.  Following cessation of the strong CYP2D6 inhibitor, the vortioxetine dose should be returned to the normal level.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786704\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786705\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Tipranavir has a moderate level of transfer across the human placenta (based on one case). Data collected by the antiretroviral pregnancy registry are insufficient to evaluate human teratogenic risk. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy); however, maternal antiretroviral medication should not be withheld due to concerns of preterm birth. Information related to stillbirth, low birth weight, and small for gestational age infants is limited. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines do not recommend tipranavir for initial use in antiretroviral-naive pregnant patients. Available pharmacokinetic data are insufficient to make dosing recommendations.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. When HIV is diagnosed during pregnancy in a female who has never received antiretroviral therapy, ART should begin as soon as possible after diagnosis. Females who become pregnant on a stable ART regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in nonpregnant adults; ART should be continued postpartum for all females living with HIV.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1039274\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The absolute CD4 cell count is currently recommended to monitor immune status in children of all ages; CD4 percentage can be used as an alternative in children &lt;5 years of age. This recommendation is based on the use of absolute CD4 cell counts in the current pediatric HIV infection stage classification and as thresholds for urgency of initiation of antiretroviral treatment (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Prior to initiation of therapy: Genotypic resistance testing, CD4 and viral load (every 3 to 4 months), CBC with differential, LFTs, BUN, creatinine, lipid panel, electrolytes, glucose, urinalysis (every 6 to 12 months), and assessment of readiness for adherence with medication regimen. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, urinalysis (at initiation), BUN, creatinine, albumin, total protein, lipid panel (at initiation), CD4, and viral load. After 1 to 2 weeks of therapy: Signs of medication toxicity and adherence. After 2 to 4 weeks of therapy: CBC with differential, viral load, and signs of medication toxicity, and adherence; then every 3 to 4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, viral load, signs of medication toxicity, and adherence. Every 6 to 12 months: Lipid panel and urinalysis. CD4 monitoring frequency may be decreased to every 6 to 12 months in children who are adherent to therapy if the value is well above the threshold for opportunistic infections, viral suppression is sustained, and the clinical status is stable for more than 2 to 3 years. In patients with known or suspected complex drug resistance patterns, phenotypic resistance testing (usually in addition to genotypic resistance testing) should be performed (HHS [pediatric] 2017). Monitor for growth and development, signs of HIV-specific physical conditions, HIV disease progression, opportunistic infections, hepatitis, or pancreatitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25017687\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma trough concentration &ge;20,500 ng/mL (based on data from treatment-experienced patient with resistant HIV-1 strains) (HHS [pediatric] 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786724\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786726\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Absorption: Incomplete (percentage not established)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 2 to &lt;6 years: 4 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 6 to &lt;12 years: 4.7 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 12 to 18 years: 5.3 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 7.7 to 10 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Protein binding: &gt;99% (albumin, alpha-1 acid glycoprotein)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Metabolism: Hepatic, via CYP3A4 (minimal when coadministered with ritonavir)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Bioavailability: Not established</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Half-life elimination: Children 2 to &lt;6 years of age: ~8 hours, 6 to &lt;12 years of age: ~7 hours, 12 to 18 years: ~5 hours; Adults: Males: 6 hours; Females: 5.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 2 to 18 years: 2.5 to 2.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Excretion: Feces (82%); urine (4%); primarily as unchanged drug (when coadministered with ritonavir)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4589246\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Aptivus Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (120): $1,893.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aptivus Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (95 mL): $631.28</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869444\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aptivus (AR, AT, AU, BB, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IS, IT, LT, LU, LV, MT, MX, NL, NZ, PL, PT, RO, RU, SE, SI, SK, TR, TW);</li>\n      <li>Elodius (BR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tipranavir-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aptivus (tipranavir) [prescribing information]. Ridgefield, CT:Boehringer Ingelheim Pharmaceuticals Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graff J, von Hentig N, Kuczka, K, et al. Significant effects of tipranavir on platelet aggregation and thromboxane B<sub>2</sub> formation <i>in vitro</i> and <i>in vivo</i>. <i>J Antimicrob Chemother</i>. 2008;61(2):394-399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tipranavir-pediatric-drug-information/abstract-text/18156609/pubmed\" target=\"_blank\" id=\"18156609\">18156609</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Accessed November 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. April 2017. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated August 6, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Last modified December 2013. Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php. Accessed December 30, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tipranavir-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 89428 Version 121.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708929\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F786677\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2935530\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1039236\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1039267\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F786742\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F786679\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1039272\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F786723\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1039237\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25708074\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F786714\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F786708\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F786709\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25955859\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F786718\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F786717\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F786704\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F786705\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1039274\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F25017687\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F786724\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F786726\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F4589246\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869444\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/89428|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tipranavir-drug-information\" class=\"drug drug_general\">Tipranavir: Drug information</a></li><li><a href=\"topic.htm?path=tipranavir-patient-drug-information\" class=\"drug drug_patient\">Tipranavir: Patient drug information</a></li></ul></div></div>","javascript":null}